Subclinical Hyperthyroidism and the Risk of Coronary Heart Disease and Mortality
University of Lausanne · Leiden University · +10 more institutions
Abstract
Data from prospective cohort studies regarding the association between subclinical hyperthyroidism and cardiovascular outcomes are conflicting.We aimed to assess the risks of total and coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation (AF) associated with endogenous subclinical hyperthyroidism among all available large prospective cohorts.
Individual data on 52 674 participants were pooled from 10 cohorts. Coronary heart disease events were analyzed in 22 437 participants from 6 cohorts with available data, and incident AF was analyzed in 8711 participants from 5 cohorts. Euthyroidism was defined as thyrotropin level between 0.45 and 4.49 mIU/L and endogenous subclinical hyperthyroidism as thyrotropin level lower than 0.45 mIU/L with normal free thyroxine levels, after excluding those receiving thyroid-altering medications.
Citation impact
- FWCI
- 24.23
- Percentile
- 100%
- References
- 63
Authors
24Topics & keywords
- Subclinical infection
- Medicine
- Hazard ratio
- Internal medicine
- Prospective cohort study
- Cohort study
- Atrial fibrillation
- Proportional hazards model
- Good health and well-being
Funding
- NSNational Science Foundation
- AHAmerican Heart Association
- UOUniversity of PittsburghAward: P30-AG-024827
- NTNorges Teknisk-Naturvitenskapelige Universitet
- CRCancer Research UK
- DFDeutsche Forschungsgemeinschaft
- SNSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungAwards: SNSF 320030-138267, 15103, 138267, 320030-138267, 20098, 320030
- FDFundação de Amparo à Pesquisa do Estado de São Paulo
- BFBundesministerium für Bildung und Forschung
- NONederlandse Organisatie voor Wetenschappelijk Onderzoek
- UGUniversität Greifswald
- MOMinistry of Cultural Affairs
- MRMedical Research Council
- NINorwegian Institute of Public Health
- NINational Institute on AgingAwards: AG-023629, R01-NR012459, N01-HC-85086, N01-AG-6-2106, AG-15928, N01 HC-15103, NIA grant R01-AG028050, N01-HC-75150, N01-HC-45133, N01-AG-6-2103, R01-AG028050, N01-HC-35129, N01-HC-85079, AG-027058, R01 AG-20098, N01 HC-55222, N01-AG-6-2101, HL080295, 024827, AG-20098, R01 AG-15928
- NHNational Heart, Lung, and Blood InstituteAwards: R01 HL-075366, AG-023629, AG-027058, R01-NR012459, AG-20098, HL-075366, N01-HC-75150, N01-HC-35129, U01 HL080295, N01-AG-6-2101, R01-AG028050, N01-HC-85079, N01-HC-45133, N01-HC-85086, N01 HC-15103, N01 HC-55222, AG-15928, N01-HC-85079 through N01-HC-85086, N01-AG-6-2103, HL080295, N01-AG-6-2106
- NINational Institute of Nursing ResearchAwards: R01-AG028050, N01-AG-6-2103, N01-AG-6-2101, N01-AG-6-2106, R01-NR012459
- NINational Institute of Neurological Disorders and StrokeAwards: N01-AG-6-2106, N01-AG-6-2103, U01 HL080295, AG-15928, N01-HC-75150, R01-NR012459, HL080295, AG-20098, N01-HC-35129, AG-027058, AG-023629, N01-HC-45133, N01-AG-6-2101, N01 HC-15103, N01-HC-85079, R01-AG028050, N01-HC-85086, N01 HC-55222